文献速递骨软组织肉瘤与黑色素瘤

年轻转移性黑色素瘤成人患者中免疫检查点抑制剂的疗效与安全性

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
PubMed 文献 · Eur J Cancer · 2022-12-27

该多机构回顾性研究纳入676例晚期黑色素瘤患者,按年龄分为≤40岁、41-70岁和≥71岁三组,比较抗PD-1单药或免疫检查点抑制剂联合治疗的疗效与毒性。≤40岁患者接受联合治疗相比单药有更高缓解率(53% vs 38%,p=0.035)和更长无进展生存期(中位13.7 vs 4.0个月,p=0.032)。各年龄组疗效相当,但>70岁患者总生存较差且联合治疗缓解率低(28%);年轻患者肝毒性更常见。

要点

  • ≤40岁患者联合ICI较单药缓解率更高(53% vs 38%,p=0.035),中位PFS更长(13.7 vs 4.0个月,p=0.032)。
  • 年轻患者单药肝毒性9% vs >40岁2%(p=0.007),联合治疗肝毒性37% vs 10%(p<0.001)。
  • >70岁患者总生存较差,联合治疗缓解率仅28%。

核心结论

  • 年轻与老年患者之间ICI疗效相当,但≤40岁患者中联合ICI相比单药结局更优。
  • 各年龄组毒性发生率相似,但受累器官存在显著差异。

研究设计与样本

  • 多机构回顾性研究,纳入676例晚期黑色素瘤患者,接受抗PD-1单药或伊匹木单抗联合抗PD-1治疗。
  • 按年龄分组:≤40岁190例(28%),41-70岁313例(46%),≥71岁173例(26%)。

主要发现

  • ≤40岁患者联合ICI相比单药缓解率更高(53% vs 38%,p=0.035),中位无进展生存期更长(13.7 vs 4.0个月,p=0.032)。
  • 各年龄组间无进展生存期相似,但>70岁患者总生存较差,且联合治疗缓解率低(28%)。
  • 年轻患者单药肝毒性发生率9% vs >40岁患者2%(p=0.007),联合ICI肝毒性37% vs 10%(p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The integration of immune checkpoint inhibitors (ICI) for the treatment of melanoma has resulted in remarkable and durable responses. Given the potential role of immunosenescence, age may contribute to differential ICI efficacy and toxicity. While older patients have been studied in detail, outcomes from ICI in young patients (≤40 years) are not well characterised. METHODS: We performed a multi-institutional, retrospective study of patients with advanced melanoma treated with anti-PD-1 monotherapy or ICI combination (ipilimumab and anti-PD-1). Response rates, survival, and toxicities were examined based on age comparing those under 40 years of age with older patients (age 41-70 and ≥ 71 years). RESULTS: A total of 676 patients were included: 190 patients (28%) aged ≤40 years, 313 (46%) between ages 41-70, and 173 patients (26%) aged ≥71. Patients ≤40 years had higher response rates (53% vs 38%, p = 0.035) and improved progression-free survival (median 13.7 vs 4.0 months, p = 0.032) with combination ICI compared to monotherapy. Progression-free survival was similar among groups while overall survival was inferior in patients >70 years, who had low response rates to combination therapy (28%). ICIs had a similar incidence of severe toxicities, though hepatotoxicity was particularly common in younger patients vs. patients >40 with monotherapy (9% vs. 2%, p = 0.007) or combination ICI (37% vs. 10%, p < 0.001). CONCLUSIONS: ICIs had comparable efficacy between younger and older patients, although outcomes were superior with combination ICI compared to monotherapy in patients aged ≤40 years. Toxicity incidence was similar across age groups, though organs affected were substantially different.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wong SK, Blum SM, Sun X, et al. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. Eur J Cancer. 2022. PMID: 36680880. doi:10.1016/j.ejca.2022.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。